Testing two blood-cancer medicines plus eDC in older MDS patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This early-phase study tests a combination of two standard medicines for myelodysplastic syndrome (MDS) along with an added eDC therapy in people age 60 and older. It may help improve blood counts or disease control for those who cannot or do not want stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 60 or older and have myelodysplastic syndrome (MDS)
- Your overall ability to function is good (ECOG score less than 1)
- Your heart, liver, and kidneys are working well enough for treatment
- Your bilirubin level is at or below 35 umol/L, and your creatinine is at or below 150 umol/L
- You cannot or do not want a stem cell transplant for this condition
- You are able and willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial tests whether adding high-dose vitamin C (ascorbate) to a standard chemotherapy drug (azacitidine) helps people with higher-risk myelodysplastic syndrome (MDS). It is for those who have had little or no prior treatment for MDS.
This trial tests a combination of two drugs (decitabine and venetoclax) at a very low, extended dose for people aged 60 or older who have been newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this gentler approach is effective and well-tolerated.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
This Phase 1 trial tests whether SX-682 given alone or with decitabine can treat myelodysplastic syndrome (MDS) that has not responded well to prior therapy. It also studies safety and the best dose, which may help people who have limited treatment options.
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.